Cancer vaccine hefty price tag for months of life extension
08/03/2010 // US // Get Cancer Answers // News Desk
U.S. – Some health experts have expressed concern over the hefty price tag attached to the first vaccine treatment for cancer. As reported by ABC News, despite the concerns, the vaccine Provenge, which is produced by Dendreon and costs $93,000 for an average four month life extension, is worth the price to some patients who have received benefit from the immunotherapy used for the advanced treatment of prostate cancer.
Bob Feutz, 84, who received the treatment in 2007, is quoted in the report as stating, “On a general basis, to survive is worth anything… I’m happy to be alive.”
Mitchell Gold, president and CEO of Dendreon, is further quoted as stating of the therapy’s pricing, “It was a laborious process. We had to raise $1.2 billion to support the development. I think we’ve come up with a price that’s acceptable. It’s priced fairly for the value we’re providing to the patients.”
The vaccine therapy has been approved by the FDA.
The latest in Cancer News
Media Information:
Address:
Phone: ——–
Url: http://getcanceranswers.org/cancer-vaccine-hefty-price-tag-for-months-of-life-extension_1721.html
Other News / Press Releases
- Mesothelioma is a Slow-Growing Cancer
- What Are the Risk Factors for Mesothelioma Cancer?
- Mother, Daughter Arrested for Obscene Facebook Video
- Report: War on Drugs is a Failure; Drug Reforms Urged
- U.S. Attorney General: New Law Will Give Crack Cocaine Offenders A Break
- Florida Governor Rick Scott Signs Welfare Drug-Screening Bill
- WHO: Cell phones are ‘Possibly Carcinogenic to Humans’
- Family Dog Crawls Home On Broken Legs After Surviving Alabama Tornado
- Desk Jobs Could be Helping You Pack on the Pounds, Driving Obesity Issue
- Organic Foods May Actually Not Be Very ‘Organic’



.png)





